secwatch.observer — SEC 8-K summary
======================================

Issuer:     Solid Biosciences Inc. (SLDB)
CIK:        0001707502
Form:       8-K
Filed at:   2022-04-27T23:59:59+00:00
Accession:  0001193125-22-121607
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Solid Biosciences restructures, cuts 35% of staff; Q1 net loss $25.3M; COO resigns
--------------------------------------------------------------------------------

- Headcount reduced ~35% to align resources behind SGT-001 and SGT-003; cash runway extended into Q2 2024.
- COO Joel Schneider to resign effective May 27, 2022 to become CEO of a private gene therapy company.
- Q1 net loss $25.3M vs $16.9M YoY; collaboration revenue $1.9M (down from $3.3M); R&D expense $19.9M.
- Cash, equivalents and securities $180.1M as of March 31, 2022.
- SGT-003 IND submission expected early 2023; SGT-001 transitioning to commercial-scale manufacturing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1707502/000119312522121607/0001193125-22-121607-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1707502/000119312522121607/d326843d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-121607

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer